Until now, it is unclear if different EGPA-phenotypes should receive tailored therapy, for instance anti-IL-5 therapy with mepolizumab for ANCA-negative EGPA. The gene discussed is IL5; the disease is eosinophilic granulomatosis with polyangiitis.